|
||||||||||||||||
|
||||||||||||||||
The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. uranium workers, 116–117, 119, 121, 128, 134–135, 138, 149 Agency for Toxic Substances and Disease Registry (ATSDR), 94, 99, 106 Air Force Technical Applications Center (AFTAC), 173 Alkaline phosphatase (ALP), 150 Aluminum hydroxide adjuvant, 274, 276 American College of Rheumatology, 355 American Psychiatric Association, 345, 346, 360 Ammunition depleted uranium, 5, 6, 92–93, 98, 326 sarin, 172 see also Armor Animal studies, 2, 71–72, 80, 99, 351 anthrax vaccines, 21, 277–280, 330 botulinum toxoid vaccines, 21, 288, 289–291, 330 cyclosarin, 186–187 depleted uranium, 99, 100–101, 151, 327 multiple vaccinations, 297–299 pain, 72 pyridostigmine bromide (PB), 209, 210–211, 213, 214, 215, 218–219, 220 sarin, 10, 175–176, 177, 178–187, 288 squalene, 308–309 uranium, 21, 96, 97–98, 99–106, 107, 151, 159, 327 vaccines, 271, 272, 277–280, 288, 289–291, 297–299, 308–309, 330 see also Primate equilibrium platform Anthrax Vaccine Expert Committee, 284 Anthrax Vaccine Immunization Program, 15, 274, 330 Anthrax vaccines, vii, 1, 2, 4, 14, 15–16, 19, 21, 28, 268, 272, 274–287, 306, 312–313, 330, 335 acute effects, 15, 16, 19, 277–287 (passim), 304, 313 animal studies, 21, 277–280, 330 antigens, general, 15, 54, 274–277 (passim), 279–280 cardiovascular system, 278, 280 cellular processes, general, 272, 276, 301, 302 chronic effects, 19, 287, 312–313 clinical studies, 15–16, 19, 282–283, 284–287, 334 dermal effects, 15, 16, 272(n.3), 279, 281–287 (passim) dose factors, 274–275, 278, 285 edema, 15, 275, 276, 277, 278, 283, 284 exposure routes, 272(n.3), 275 ingestion, 272(n.3) inhalation, 272(n.3), 276–277, 282, 283 injection delivery, 15, 279–286 (passim), 297 FDA, 14, 267, 274, 283–284, 287, 313 fever, 16, 277–278, 282, 284, 285, 287 gastrointestinal effects, 272(n.3), 285 gender factors, 286 genetic effects, 280 historical perspectives, 272, 274, 281, 283–284, 287 hospitalization following administration, 284, 286 immune system pathologies, 279, 284, 285, 290–292, 306 inflammation, 278, 281, 284, 286, 287, 297 live attenuated spore vaccines, 274, 276, 277–279, 281, 297 lymphatic system, 278 mental disorders, 284 multiple vaccinations, 301, 304 neuromuscular effects, 281, 284, 285, 286 neuropathy, general, 285 number of vaccinations given, 15, 267, 274, 284 protective antigen vaccines, 274, 276–277, 279–280, 281, 282 reproductive system effects, 226
|
|
|||||||||||||||
